Efficacy and safety of long‐term treatment with cyclosporin A for atopic dermatitis
- 14 November 2006
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 21 (1), 85-89
- https://doi.org/10.1111/j.1468-3083.2006.01877.x
Abstract
Cyclosporin A (CsA) is being increasingly used in the treatment of severe refractory atopic dermatitis. Clinical efficacy and safety of short-term cyclosporin A treatment in atopic dermatitis patients has been proven, however, data on long-term treatment are limited. The aim of this study was to investigate the efficacy, safety and the effect of discontinuation of cyclosporin A treatment in atopic dermatitis patients, with a particular focus on patients treated with cyclosporin A for more than 6 months. We performed a retrospective study of clinical and adverse effects of cyclosporin A treatment in 73 atopic dermatitis patients, with an average duration of cyclosporin A treatment of 1.3 years. We included 73 patients (31 women and 42 men, with a mean age of 33.8 years) with severe atopic dermatitis refractory to conventional therapy that was treated with cyclosporin A. Treatment was successful in 56/73 patients. Increases in serum creatinine levels > 30% compared to baseline were reported in 7/73 patients. Arterial hypertension appeared in 11/73 patients during treatment. After discontinuation of treatment, 40/73 patients experienced a relapse and 33/73 patients experienced clinical remission for at least 3 months. No correlation between treatment duration and nephrotoxicity or hypertension was found. Strikingly, 6/73 patients experienced a rebound phenomenon. We conclude that CsA is an effective and safe treatment for patients with severe AD refractory to conventional treatment, provided that the recommended guidelines for its administration are strictly observed. However, in contrast to previous reports, we found that 8% (6/73) of patients experienced a rebound phenomenon after discontinuation of treatment.Keywords
This publication has 14 references indexed in Scilit:
- Manifestation of Atopic Eczema in Children after Heart Transplantation in the First Year of LifePediatric Dermatology, 2005
- Cyclosporin in Atopic DermatitisDermatology, 1999
- Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitisBritish Journal of Dermatology, 1997
- The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimensBritish Journal of Dermatology, 1996
- Potentiation of in vitro synthesis of human IgE by cyclosporin A (CsA)Clinical and Experimental Immunology, 1995
- Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapyBritish Journal of Dermatology, 1995
- Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trialBritish Journal of Dermatology, 1993
- Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitisThe Lancet, 1991
- Side-effect profile of cyclosporin A in patients treated for psoriasisBritish Journal of Dermatology, 1990
- RISK OF CANCER IN RENAL-TRANSPLANT RECIPIENTSThe Lancet, 1973